Galectin Therapeutics Inc. (NASDAQ:GALT) Position Increased by Retirement Guys Formula LLC

Retirement Guys Formula LLC raised its holdings in shares of Galectin Therapeutics Inc. (NASDAQ:GALT) by 56.9% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 33,732 shares of the company’s stock after buying an additional 12,232 shares during the period. Retirement Guys Formula LLC owned about 0.05% of Galectin Therapeutics worth $81,000 as of its most recent SEC filing.

Separately, Solutions 4 Wealth Ltd purchased a new stake in shares of Galectin Therapeutics in the 4th quarter valued at approximately $60,000. 11.68% of the stock is owned by institutional investors and hedge funds.

Galectin Therapeutics Trading Down 5.7 %

Galectin Therapeutics stock opened at $2.15 on Friday. The company has a market capitalization of $133.62 million, a P/E ratio of -2.91 and a beta of 0.63. The firm’s fifty day simple moving average is $2.82 and its 200-day simple moving average is $2.40. Galectin Therapeutics Inc. has a 1-year low of $1.35 and a 1-year high of $4.27.

Galectin Therapeutics (NASDAQ:GALT) last released its quarterly earnings results on Wednesday, May 15th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.03). On average, equities research analysts predict that Galectin Therapeutics Inc. will post -0.66 earnings per share for the current year.

Wall Street Analyst Weigh In

GALT has been the subject of several research analyst reports. HC Wainwright restated a “buy” rating and issued a $11.00 price target on shares of Galectin Therapeutics in a research report on Tuesday, April 9th. StockNews.com downgraded shares of Galectin Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, May 29th.

Insider Activity at Galectin Therapeutics

In related news, major shareholder James C. Czirr sold 21,323 shares of the firm’s stock in a transaction on Monday, April 22nd. The shares were sold at an average price of $3.06, for a total value of $65,248.38. Following the transaction, the insider now directly owns 5,925,884 shares in the company, valued at approximately $18,133,205.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last three months, insiders have bought 4,500 shares of company stock worth $14,360. 52.70% of the stock is owned by insiders.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.